Stock APGN APEXIGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Apexigen, Inc.

Equities

APGN

US03759B1026

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
BU
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
AQ
APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
BU
Shareholder Alert: Ademi LLP investigates whether Apexigen, Inc. has obtained a Fair Price in its transaction with Pyxis Oncology
PR
APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders
BU
Pyxis Oncology to Acquire Apexigen
AQ
APEXIGEN, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
APEXIGEN, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Apexigen Announces Review of Strategic Alternatives and Restructuring
AQ
APEXIGEN, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
APEXIGEN, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
APEXIGEN, INC. : Unregistered Sale of Equity Securities (form 8-K)
AQ
APEXIGEN, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Apexigen Announces Approximately $2.8 Million Private Placement Financing
AQ
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023
AQ
Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update
AQ
Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma
AQ
Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting
AQ
Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
AQ
Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APGN Stock
  4. News Apexigen, Inc.
  5. Press Releases